Ondine Biomedical Inc on Friday said it received approval to market Steriwave in the United Arab Emirates.

The Vancouver-based company specialising in photodisinfection-based therapies said with the approval, it is able to market Steriwave nasal decolonisation to reduce healthcare-associated infections in patients undergoing surgery in the country.

Chief Executive Officer Carolyn Cross said: ‘We are looking forward to bringing the infection-reducing benefits of Steriwave nasal decolonization to the United Arab Emirates and other Middle Eastern Markets. We believe that adding Steriwave to current presurgical and intensive care unit protocols can help these countries to address the growing threat from antimicrobial resistant infections in hospitals.’

Steriwave uses a light-activated agent to quickly eliminate infection-causing pathogens in a single five-minute treatment.

Ondine shares rose 3.9% to 6.63 pence each on Friday morning in London.

Copyright 2024 Alliance News Ltd. All Rights Reserved.